2025 Accreditation
The AAFP has reviewed NJAFP 2025 Annual Meeting and deemed it acceptable for AAFP credit. Term of Approval is from 05/02/2025 to 05/04/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This session, NJAFP Annual Meeting, is approved for 9.75 Live AAFP Prescribed credit(s).
This session, KSA - Health Counseling and Preventive Care, is approved for 8.00 Knowledge Self-Assessment, Live AAFP Prescribed credit(s).
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
Disclosures of Conflicts of Interest
Presenters - no conflicts
Francis Bellino, MD, FAAFP, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
David Cennimo, MD, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Donna M. Kaminski, DO, MPH, FAAFP, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Jeffrey Levine, MD, MPH, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Melany Rivera Maldonado, PhD, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Everett Schlam, MD, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Anna Silwowska, MD, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Meera Wells, MD, faculty for this educational event, has no relevant financial relationship(s) with ineligible companies to disclose.
Conflict Disclosures
Cresandra Corbin, MD, FAAFP, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for Organon
Vikas Dharnidharka, MD, MPH, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for CSL Vifor, Akebia and Vera Therapeutics
P. Barton Duell, MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for Ionis, Novo Nordisk, Regeneron, Mirum and New Amsterdam
Janet B. McGill, MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for Bayer HealthCare Pharmaceuticals, Inc., Lilly, Novo Nordisk, and Mannkind Corporation.
o Researcher for Diamyd, Biomea, Lexicon - all grants to WU
Javier Morales, MD, FACP, FACE, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for Novo Nordisk, Eli Lilly, Amgen, Boehringer Ingelheim, Bayer
Rebecca Levy, JD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Owner/Stockholder for Summit Health and Vanova Health
o Employee/Executive Role for Vanova Health
Sally Mvarack, MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Speakers Bureau for Gilead Sciences
o Individual Stocks/Stock Options in Eli Lily; Novo Nordisc
Anjali Tiku Owens, MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for BioMarin, Bristol Myers Squibb, Cytokinetics, Edgewise Therapeutics, Lexicon Pharmaceuticals, Inc., Pfizer, Renovacor, Inc., Stealth Bio Therapeutics, Inc., and Tenaya Therapeutics.
o Grant/Research Support from Bristol Myers Squibb
Reynold Panettieri, Jr., MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisory Boards for AstraZeneca, Clarivate, RIFM, Sanofi, and Regeneron.
o Consultant for Chiesi and Syneos
o Speakers Bureau for Genentech, GSK, and AgoMab.
o Researcher for Origo
Donna Ryan, MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Advisor/Consultant for AbbVie, Altimmune, Amgen, AstraZenica, Biohaven, Boehringer Ingelheim, Calibrate, Carmot/Roche, Curraz, CinRX, eMedd, Epitomee, Lilly, Nestle, Novo Nordisk, Pfizer, PPD, Regeneron, Scientific Intake, Structure Therapeutics, Source Bio, TenVie, Wondr Health, Zealand, Fractyl, and Gila Therapeutics.
o Speakers Bureau for Lilly, and Novo Nordisk.
o Stock Shareholder in Calibrate Health; Epitomee Medical ltd.; Roman; and Scientific Intake Limited Co.
Jihad Slim MD, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Speakers Bureau for Gilead, and ViiV.
James Underberg, MD, FACP, MNLA, faculty for this educational event, has relevant financial relationship(s) with ineligible companies to disclose.
o Speakers Bureau for Regeneron, Amgen, and Esperion.
o Advisor/Consultant for Ionis, Arrowhead and New Amsterdam.
All of the relevant financial relationships listed for these individuals have been mitigated.
Planner disclosures
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients